PFNX - Pfenex Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
13.35
+0.25 (+1.91%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close13.10
Open13.47
Bid12.61 x 800
Ask18.00 x 2200
Day's Range13.08 - 13.91
52 Week Range3.95 - 13.95
Volume419,789
Avg. Volume328,593
Market Cap422.873M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.48
Earnings DateMar 08, 2020 - Mar 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
  • Announcing: Pfenex (NYSEMKT:PFNX) Stock Increased An Energizing 178% In The Last Year
    Simply Wall St.

    Announcing: Pfenex (NYSEMKT:PFNX) Stock Increased An Energizing 178% In The Last Year

    When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...

  • Thomson Reuters StreetEvents

    Edited Transcript of PFNX earnings conference call or presentation 7-Nov-19 9:30pm GMT

    Q3 2019 Pfenex Inc Earnings Call

  • GlobeNewswire

    Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL®, containing CRM197 produced in Pfenex Expression Technology

    Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization (WHO) prequalification for Pneumosil, a 10-valent pneumococcal conjugate vaccine. Pneumosil contains the recombinant carrier protein CRM197 produced by Serum Institute under a license to the Pfenex Expression Technology®. Under the agreement with Serum Institute, Pfenex is eligible to receive annual fees, milestone payments, and a tiered low single digit royalty based on net sales for all products developed by Serum Institute that use the CRM197 carrier protein produced via the Pfenex Expression Technology.

  • Hedge Funds Have Never Been This Bullish On Pfenex Inc (PFNX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Pfenex Inc (PFNX)

    Is Pfenex Inc (NYSE:PFNX) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]

  • GlobeNewswire

    Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals

    Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated with process development activities for PF745, a long-acting Erwinia asparaginase. “We are very pleased with the rapid progression of the PF745 program and we believe the Jazz collaboration, overall, further validates the versatility of our proprietary protein expression platform and the quality of our development capabilities,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. Under the terms of the development and license agreement, Pfenex is eligible to receive an aggregate total of up to $224.5 million in development and sales milestones, of which $162.5 million is still eligible to be received by Pfenex, including up to $3.5 million for development milestones, $34 million in regulatory milestones and $125 million in sales milestones.

  • GlobeNewswire

    Pfenex to Present at the Piper Jaffray 31st Annual Healthcare Conference

    SAN DIEGO, Nov. 20, 2019 -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to.

  • GlobeNewswire

    Pfenex to Present at the Evercore ISI HealthCONx Conference 2019

    SAN DIEGO, Nov. 19, 2019 -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to.

  • GlobeNewswire

    Pfenex Announces Management Change

    Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial Officer effective November 13, 2019, but will continue to support the company by providing transition services until February 1, 2020. Pfenex's expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

  • Pfenex (PFNX) Matches Q3 Earnings Estimates
    Zacks

    Pfenex (PFNX) Matches Q3 Earnings Estimates

    Pfenex (PFNX) delivered earnings and revenue surprises of 0.00% and 3.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Pfenex Reports Third Quarter 2019 Results and Provides Business Update

    Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA.

  • GlobeNewswire

    Pfenex to Present at the Jefferies 2019 London Healthcare Conference

    SAN DIEGO, Nov. 06, 2019 -- Pfenex Inc. (NYSE American: PFNX) today announced that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the.

  • Pfenex (PFNX) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks

    Pfenex (PFNX) Reports Next Week: Wall Street Expects Earnings Growth

    Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Pfenex to Announce Third Quarter 2019 Financial Results on November 7th

    SAN DIEGO, Oct. 24, 2019 -- Pfenex Inc. (NYSE American: PFNX), a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to.

  • Will Pfenex (NYSEMKT:PFNX) Spend Its Cash Wisely?
    Simply Wall St.

    Will Pfenex (NYSEMKT:PFNX) Spend Its Cash Wisely?

    There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Pfenex (NYSEMKT:PFNX...

  • GlobeNewswire

    Pfenex Reports Positive Results for PF708 Comparative Use Human Factors Study

    Pfenex Inc. (NYSE American: PFNX) announced today it has successfully completed the PF708 comparative use human factors (HF) study and submitted the final study report to the FDA. The study found that the user interface of the FDA-approved PF708 product was noninferior to that of Forteo® for each critical user task evaluated in the study.

  • Implied Volatility Surging for Pfenex (PFNX) Stock Options
    Zacks

    Implied Volatility Surging for Pfenex (PFNX) Stock Options

    Investors need to pay close attention to Pfenex (PFNX) stock based on the movements in the options market lately.

  • GlobeNewswire

    Pfenex Provides Update for PF708 Outside the United States

    Pfenex Inc. (NYSE American: PFNX) today announced that its partner Alvogen has entered into exclusive commercialization agreements for PF708 with PharmBio Korea in South Korea, JAMP Pharma in Canada and Kamada Ltd. in Israel. Furthermore, Alvogen’s partner in the Middle East and North Africa (MENA) region, SAJA, submitted a Marketing Authorization Application (MAA) to the Kingdom of Saudi Arabia's Saudi Food and Drug Authority (SFDA).

  • GlobeNewswire

    Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis

    Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA) has approved the new drug application (“NDA”) for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo® (teriparatide injection) as the reference drug. “The FDA’s approval of PF708 marks a major milestone in Pfenex’s history as our first approved commercial product and further validates our Pfēnex Expression Technology platform.

  • Benzinga

    Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar

    Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value protein-based therapeutics and vaccines. The most advanced product candidate in Pfenex' pipeline, PF708, is inching closer to commercialization.

  • GlobeNewswire

    Pfenex to Present at the Cantor Healthcare Conference

    SAN DIEGO, Sept. 16, 2019 -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire

    Pfenex to Participate in the Oppenheimer Fall Summit

    SAN DIEGO, Sept. 10, 2019 -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire

    Pfenex Earns $11 Million Development Milestone under its Development and License Agreement with Jazz Pharmaceuticals

    Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agreement with Jazz Pharmaceuticals. The milestone is associated with process development activities for PF745, a recombinant crisantaspase with half-life extension technology. “We are very pleased with our progress on PF745 and we believe the Jazz collaboration overall further validates the versatility of our proprietary protein expression platform and the quality of our development capabilities,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex.

  • GlobeNewswire

    Pfenex Appoints Dr. Steve Kay to Scientific Advisory Board

    Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the appointment of Steve Kay, Ph.D., to the Pfenex Scientific Advisory Board. “Dr. Kay is a highly regarded biologist that brings a wealth of research experience to our Scientific Advisory Board and will complement the existing board in support of the Pfenex scientific strategy. Steve joins several other respected scientists and physicians we have recently appointed to executive and advisory roles in the company to support our evolving R&D strategy with a goal of further leveraging the Pfēnex Expression Technology platform to expand our development pipeline,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex.

  • Thomson Reuters StreetEvents

    Edited Transcript of PFNX earnings conference call or presentation 8-Aug-19 8:30pm GMT

    Q2 2019 Pfenex Inc Earnings Call

  • Pfenex (PFNX) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Pfenex (PFNX) Reports Q2 Loss, Misses Revenue Estimates

    Pfenex (PFNX) delivered earnings and revenue surprises of 4.00% and -50.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?